Publication | Open Access
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
2.1K
Citations
21
References
2011
Year
Bevacizumab improved progression-free survival in women with ovarian cancer. The benefits with respect to both progression-free and overall survival were greater among those at high risk for disease progression. (Funded by Roche and others; ICON7 Controlled-Trials.com number, ISRCTN91273375.).
| Year | Citations | |
|---|---|---|
Page 1
Page 1